A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 277
- Locations
- 66
- Primary Endpoint
- Difference between responder rates of the treatment & control groups, responders defined as subjects with clinically meaningful improvements in disease-related health status (SGRQ) & regional lung volume changes as measured by quantitative CT scan.
Study Overview
Brief Summary
This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IBV Valve at redirecting airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status.
Detailed Description
The IBV Valve Trial is a multi-center clinical trial evaluating the IBV Valve System, a non-surgical treatment for patients with emphysema. The IBV Valve System does not require traditional surgery or surgical incisions. The valves are placed during a bronchoscopic procedure. The IBV Valve System is designed to redirect airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status. Although the valves are intended to be permanent, they are designed to be removed if necessary.
The IBV Valve Trial is a randomized, blinded trial. This means that participants are divided into two groups but do not know to which group they have been assigned.
The IBV Valve Treatment Group receives valves, and the Control Group does not. A random selection process decides the group assignments (participants will not be able to choose their group). In the trial, everyone will have a 50 percent chance (similar to a coin toss) to be assigned to one group or the other.
All Participants in this Clinical Trial will:
Receive a diagnostic bronchoscopy that will allow an expert in lung health to evaluate their lungs.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 74 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Candidates have mostly upper lobe, severe emphysema.
- •Must be able to participate in standard exercise testing.
- •Willing to abstain from cigarette smoking for 4 months prior and during the entire trial.
- •Willing to participate in a randomized, blinded study and complete the required follow-up visits during the study period.
- •Willing to participate in multiple visits to a medical center for health assessment tests.
- •Willing to have a minimum of one overnight stay in the hospital.
Exclusion Criteria
- •Evidence of another co-existing major medical disease.
- •Unable to tolerate, flexible bronchoscopy procedures.
- •Active asthma, chronic bronchitis.
- •Diffuse emphysema pattern, alpha 1-antitrypsin deficiency.
- •Has had prior lung volume reduction surgery.
Arms & Interventions
1
The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
Intervention: IBV® Valve System (Device)
2
The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
Intervention: IBV® Valve System (Device)
Outcomes
Primary Outcomes
Difference between responder rates of the treatment & control groups, responders defined as subjects with clinically meaningful improvements in disease-related health status (SGRQ) & regional lung volume changes as measured by quantitative CT scan.
Time Frame: 6 months
Secondary Outcomes
- The difference between average 6 minute walk test results for treatment & control groups.(6 months)